COMP <GO>
KRYS vs QGEN // EV/EBITDA & P/E VALUATION
Krystal Biotech Inc. (NASDAQ) VS. Qiagen N.V. (NYSE) • 15-METRIC TALLY: KRYS 5
— QGEN 8
▲ EV/EBITDA & P/E VALUATION LEADER: QGEN
LAST: $332.29 (+2.38%) • MKT CAP: $9.61B
valuation
53.4x
LAST: $50.22 (-0.24%) • MKT CAP: $10.37B
valuation
17.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRYS VS. QGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRYS | QGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 62.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 8.00% | +8.50 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 53.4x | 17.6x | +35.80 | QGEN | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | 4.37% | -2.40 | QGEN | /fcf-yield <GO> |
| Operating Margin | 41.50% | 22.30% | +19.20 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 52.60% | 20.30% | +32.30 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 33.90% | 5.70% | +28.20 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.52% | -0.52 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.54 | +22.46 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.2 | 72.4 | -24.20 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.95 | -0.04 | QGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.4x | 22.7x | +16.70 | QGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.61B | $10.37B | -$767.5M | QGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRYS REV | QGEN REV | KRYS GROSS % | QGEN GROSS % | KRYS FCF | QGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $2.09B | — | 62.2% | $188.9M | $453.3M |
| FY 2024 | $290.5M | $1.98B | — | 48.9% | $119.2M | $506.4M |
| FY 2023 | $50.7M | $1.97B | — | — | -$91.1M | $371.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRYS // BETA 0.91
QGEN // BETA 0.95